针对胰腺癌的谷氨酸依赖性,使其易受GPX4依赖性铁亡的侵害
Xuqing Shen1, Yueyue Chen1, Yingying Tang1
1State Key Laboratory of Systems Medicine for Cancer, Stem Cell Research Center, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cell reports. Medicine
|January 29, 2025
概括
胰腺癌细胞通过激活表观遗传变化来适应谷氨酸限制,从而使它们易受铁灭症的影响. 向谷氨胺依赖使PDAC对GPX4抑制剂敏感,提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 胰腺管腺癌 (PDAC) 在很大程度上依赖谷氨来满足代谢和生物合成的需求.
- 表观遗传调节剂在PDAC的代谢灵活性和适应营养稀缺性的作用尚不清楚.
研究的目的:
- 研究PDAC适应谷氨胺限制的表观遗传机制.
- 探索在PDAC中准谷氨胺代谢的治疗潜力.
主要方法:
- 通过CRISPR-Cas9查,识别参与PDAC对谷氨酸缺乏反应的表观遗传调节者.
- 在体外和体内实验中使用谷氨胺抗剂 (DON) 和GPX4抑制剂进行实验.
- 对表观遗传修饰 (H3K4me3) 和基因表达 (Hmox1,Slc7a11,Gpx4) 的分析.
主要成果:
- 胺胺限制或DON治疗抑制了PDAC的生长,并激活了ferroptosis.
- Paxip1被确定为一种表观遗传调节剂,在DON治疗后可对H3K4me3和Hmox1进行上调.
- PDAC细胞通过增加铁灭抑制剂 (Slc7a11,Gpx4) 来适应谷氨酸缺乏,使他们容易发生铁灭.
- 在体外和PDX模型中,DON使PDAC细胞对GPX4抑制剂诱导的铁化敏感.
结论:
- 向谷氨胺依赖会通过表观遗传改造诱导对GPX4依赖性铁亡的易感性.
- 针对谷氨胺代谢和GPX4的组合疗法是PDAC治疗的有希望的策略.
相关概念视频
01:33Cancer-Critical Genes I: Proto-oncogenes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...